Skip to main content
SpringerLink
Log in

A Modeling and Simulations Framework to Support Global Regulatory Strategies for Pediatric Drug Development Programs

  • Special Section: Maternal and Child Health Therapeutics
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Trial simulations have emerged as a promising tool to optimize pediatric drug development programs. As the current FDA legislation on pediatric drugs and devices was updated to mirror the EMA legislation, pediatric programs must be developed with global strategies that support a Pediatric Investigation Plan (PIP) for the EMA and a Pediatric Study Plan (PSP) for the FDA. A pharmacometrics framework is proposed to support global regulatory strategies for pediatric drug development programs. The framework describes specific trigger points and opportunities for applying modeling and simulation techniques to design the PIP and PSP and ultimately optimize pediatric drug development programs. The development of pediatric protocols by simulations and execution plans is deemed critical in defining expectations and ensuring the future success of these global programs. This can lead to clinical trial designs that are more efficient, less prone to failure, and ultimately, less costly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Happu K, Hirschfeld S, Zajicek A. Comparison of the US and EU pediatric initiatives. In: Proceedings of WHO Expert Consultation on Essential Medicines for Children; July 9–13, 2007; Geneva, Switzerland.

  2. Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010; 2(4):364–388.

    Article  Google Scholar 

  3. US Department of Health and Human Services. Pediatric product development. FDA Safety and Innovation Act. Title V for pediatric drugs and devices. Food and Drug Administration Web site.https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm. Accessed July 1, 2013.

  4. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297(5):480–488.

    Article  CAS  Google Scholar 

  5. Benjamin DK Jr., Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51(4):834–840.

    Article  CAS  Google Scholar 

  6. Lesko LF. The role of model-based drug development in paving the critical path. In: AAPS Workshop on Quantitative Clinical Pharmacology; November 10, 2007.

  7. Food and Drug Administration. Challenges and opportunities report—March 2004. Challenge and opportunity on the critical path to new medical products. FDA critical path initiatives white paper. https://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Published 2004. Accessed July 1, 2013.

  8. European Medicines Agency. The European pediatric initiative: History of the pediatric regulation. https://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003693.pdf. Accessed July 1, 2013.

  9. Bellanti F, Della Pasqua O. Modeling and simulation as research tools in pediatric drug development. Eur J Clin Pharmacol. 2011;67(suppl 1):75–86.

    Article  CAS  Google Scholar 

  10. Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7(2):E475–E487.

    Article  Google Scholar 

  11. Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B. Physiologically-based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40–49.

    Article  CAS  Google Scholar 

  12. Wildt SN, Knibbe CA. Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. Eur J Clin Pharmacol. 2009;65:849–850.

    Article  Google Scholar 

  13. Van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Br J Clin Pharmacol. 2013;76(1):30–47.

    Article  Google Scholar 

  14. US Department of Health and Human Services. Pediatric product development. Pediatric study plan. Food and Drug Administration Web site. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM338453.pdf.

  15. US Department of Health and Human Services. Exposure-response relationships—study design, data analysis, and regulatory applications. Food and Drug Administration Web site. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf. Accessed July 1, 2013.

  16. Jadhav PR, Kern SE. The need for modeling and simulation to design clinical investigations in children. J Clin Pharmacol. 2010;50:121S–129S.

    Article  Google Scholar 

  17. Mouksassi MS, Marier JF, Cyran J, Vinks AA. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther. 2009;86(6):667–671.

    Article  CAS  Google Scholar 

  18. Läer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol. 2009;49(8):889–904.

    Article  Google Scholar 

  19. Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 2005;7(3):E503–E512.

    Article  Google Scholar 

  20. Sheiner LB. Learning and confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275–291.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharsight Corporation, Montreal, Quebec, Canada

    Jean-Francois Marier PhD, FCP

  2. Duke Clinical Research Unit, Durham, NC, USA

    Barry Mangum PharmD & Betsy Reid MBA

  3. Colket Translational Research Building, The Children’s Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, 19104, USA

    Jeffrey S. Barrett PhD, FCP

  4. Kinetic Modeling and Simulation, University of Pennsylvania Medical School, Philadelphia, PA, USA

    Jeffrey S. Barrett PhD, FCP

Authors
  1. Jean-Francois Marier PhD, FCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry Mangum PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Betsy Reid MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey S. Barrett PhD, FCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey S. Barrett PhD, FCP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marier, JF., Mangum, B., Reid, B. et al. A Modeling and Simulations Framework to Support Global Regulatory Strategies for Pediatric Drug Development Programs. Ther Innov Regul Sci 47, 550–556 (2013). https://doi.org/10.1177/2168479013500289

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479013500289

Keywords

Search

Navigation